73

Oncology
Prevention and treatment of tumors, and caring for cancer patients.
Sub Categories on Oncology
Latest Articles
One in five GPs unwilling to prescribe aspirin to people at risk of bowel cancer, finds UK study

One in five GPs unwilling to prescribe aspirin to people at risk of bowel cancer, finds UK study

by University of LeedsCredit: Unsplash/CC0 Public DomainOne in five GPs could be unwilling to prescribe aspirin to patients with a cancer-causing syndrome, despite national guidelines advising it

One in five GPs unwilling to prescribe aspirin to people at risk of bowel cancer, finds UK study

by University of LeedsCredit: Unsplash/CC0 Public DomainOne in five GPs could be unwilling to prescribe aspirin to patients with a cancer-causing syndrome, despite national guidelines advising it
Study finds the mechanism used by metastatic cancer cells to infiltrate the liver

Study finds the mechanism used by metastatic cancer cells to infiltrate the liver

by ResearchSEAThe liver sinusoidal endothelial cells (LSECs, beige) surround a blood vessel containing a cancer cell (green). The cancer cell is able to induce the formation of intracellular gaps

Study finds the mechanism used by metastatic cancer cells to infiltrate the liver

by ResearchSEAThe liver sinusoidal endothelial cells (LSECs, beige) surround a blood vessel containing a cancer cell (green). The cancer cell is able to induce the formation of intracellular gaps
Everolimus inhibits angiogenesis and lymphangiogenesis in TP53 mutant HNSCC via STAT3/HIF-1α/VEGF pathway

Everolimus inhibits angiogenesis and lymphangiogenesis in TP53 mutant HNSCC via STAT3/HIF-1α/VEGF pathway

by Impact Journals LLCEverolimus reduces microvessel density (MVD) and lymphatic vessel density (LVD) in TP53 mutant HNSCC xenografts. Credit:Oncotarget(2023). DOI: 10.18632/oncotarget.283

Everolimus inhibits angiogenesis and lymphangiogenesis in TP53 mutant HNSCC via STAT3/HIF-1α/VEGF pathway

by Impact Journals LLCEverolimus reduces microvessel density (MVD) and lymphatic vessel density (LVD) in TP53 mutant HNSCC xenografts. Credit:Oncotarget(2023). DOI: 10.18632/oncotarget.283
Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an accepta

Telisotuzumab vedotin shows durable response in some Asian patients with nonsquamous NSCLC

by International Association for the Study of Lung CancerCredit: Pixabay/CC0 Public DomainThe c-Met-directed antibody-drug conjugate telisotuzumab vedotin demonstrated durable responses and an accepta
A window into the changing tumor microenvironment

A window into the changing tumor microenvironment

by Ludwig Cancer ResearchGraphical abstract. Credit:iScience(2022). DOI: 10.1016/j.isci.2022.104570Researchers led by Ludwig Lausanne's Anoek Zomer, Davide Croci and Johanna Joyce

A window into the changing tumor microenvironment

by Ludwig Cancer ResearchGraphical abstract. Credit:iScience(2022). DOI: 10.1016/j.isci.2022.104570Researchers led by Ludwig Lausanne's Anoek Zomer, Davide Croci and Johanna Joyce
Study explores why patients skip appointments for suspected cancer

Study explores why patients skip appointments for suspected cancer

by Shelley Hughes,University of YorkCredit: CC0 Public DomainMen, the elderly and people from deprived areas are among the patients most likely to miss an urgent referral appointment for suspect

Study explores why patients skip appointments for suspected cancer

by Shelley Hughes,University of YorkCredit: CC0 Public DomainMen, the elderly and people from deprived areas are among the patients most likely to miss an urgent referral appointment for suspect
Team discovers broken 'brake' of cancer mutation machine

Team discovers broken 'brake' of cancer mutation machine

by UT Southwestern Medical CenterCredit:Cancer Cell(2023). DOI: 10.1016/j.ccell.2023.06.010Loss of a gene known as SYNCRIP in prostate cancer tumors unleashes cellular machinery that

Team discovers broken 'brake' of cancer mutation machine

by UT Southwestern Medical CenterCredit:Cancer Cell(2023). DOI: 10.1016/j.ccell.2023.06.010Loss of a gene known as SYNCRIP in prostate cancer tumors unleashes cellular machinery that
Accurately diagnosing genetic disease prevents cancer, saves lives

Accurately diagnosing genetic disease prevents cancer, saves lives

by The Ohio State University Comprehensive Cancer CenterCredit: CC0 Public DomainA single, upfront genomic test is more effective for detecting Lynch syndrome in colorectal cancer (CRC) patients than

Accurately diagnosing genetic disease prevents cancer, saves lives

by The Ohio State University Comprehensive Cancer CenterCredit: CC0 Public DomainA single, upfront genomic test is more effective for detecting Lynch syndrome in colorectal cancer (CRC) patients than
Cancer-seeking molecular delivery system could boost immunotherapy drug, research finds

Cancer-seeking molecular delivery system could boost immunotherapy drug, research finds

byUniversity of Rhode IslandCredit: Unsplash/CC0 Public DomainResearchers from the University of Rhode Island and Yale University have demonstrated a promising new approach to delivering immunot

Cancer-seeking molecular delivery system could boost immunotherapy drug, research finds

byUniversity of Rhode IslandCredit: Unsplash/CC0 Public DomainResearchers from the University of Rhode Island and Yale University have demonstrated a promising new approach to delivering immunot
Fixed-duration ibrutinib plus venetoclax may benefit patients with high-risk chronic lymphocytic leukemia

Fixed-duration ibrutinib plus venetoclax may benefit patients with high-risk chronic lymphocytic leukemia

by American Association for Cancer ResearchCredit: CC0 Public DomainFirst-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic l

Fixed-duration ibrutinib plus venetoclax may benefit patients with high-risk chronic lymphocytic leukemia

by American Association for Cancer ResearchCredit: CC0 Public DomainFirst-line ibrutinib (Imbruvica) plus venetoclax (Venclexta) led to high response and survival rates in patients with chronic l
Researchers characterize mechanism of action of CAR T cells

Researchers characterize mechanism of action of CAR T cells

by H. Lee Moffitt Cancer Center & Research InstituteScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDThe sci

Researchers characterize mechanism of action of CAR T cells

by H. Lee Moffitt Cancer Center & Research InstituteScanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor. Credit: NIAIDThe sci
Mental health screenings urged for men with prostate cancer

Mental health screenings urged for men with prostate cancer

byUniversity of South AustraliaCredit: Unsplash/CC0 Public DomainMental health screenings must be incorporated into routine prostate cancer diagnoses say University of South Australia researcher

Mental health screenings urged for men with prostate cancer

byUniversity of South AustraliaCredit: Unsplash/CC0 Public DomainMental health screenings must be incorporated into routine prostate cancer diagnoses say University of South Australia researcher